Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Wilson

Showing results (231-240 of 261) with videos related to

Pageof 27
Sort By:
Biology|August 26, 2023
Prediction of Feed Efficiency and Performance-Based Traits in Fish via Integration of Multiple Omics and Clinical CovariatesTim Young, Olivier Laroche, Seumas P Walker, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 29, 2025
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trialThomas Aparicio, Anthony Turpin, Aziz Zaanan, et al.
Scientific Reports|February 17, 2016
HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo ActivationKaifan Dai, Salar N Khan, Yimeng Wang, et al.
Cancer Chemotherapy and Pharmacology|April 23, 2003
Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly scheduleXiao-Du Guo, Nancy Harold, M Wasif Saif, et al.
Nucleic Acid Therapeutics|April 1, 2022
An Integrative Multi-Omics Analysis Reveals MicroRNA-143 as a Potential Therapeutic to Attenuate Retinal AngiogenesisJiang-Hui Wang, Yu-Fan Chuang, Jinying Chen, et al.
Journal of Virology|August 10, 2012
HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteinsYuxing Li, Sijy O'Dell, Richard Wilson, et al.
Frontiers in Immunology|August 9, 2024
mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodiesJavier Guenaga, Mehrdad Alirezaei, Yu Feng, et al.
JCO Clinical Cancer Informatics|April 18, 2019
A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the ClinicManuela Salvucci, Arman Rahman, Alexa J Resler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2011
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignanciesDavid Olmos, Douglas Barker, Rohini Sharma, et al.
Cellular and Molecular Life Sciences : CMLS|August 4, 2019
Two of a kind: transmissible Schwann cell cancers in the endangered Tasmanian devil (Sarcophilus harrisii)Amanda L Patchett, Tim H H Coorens, Jocelyn Darby, et al.
Pageof 27

Showing results (231-240 of 261) with videos related to

Sort By:
Pageof 27
Biology|August 26, 2023
Prediction of Feed Efficiency and Performance-Based Traits in Fish via Integration of Multiple Omics and Clinical CovariatesTim Young, Olivier Laroche, Seumas P Walker, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 29, 2025
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trialThomas Aparicio, Anthony Turpin, Aziz Zaanan, et al.
Scientific Reports|February 17, 2016
HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo ActivationKaifan Dai, Salar N Khan, Yimeng Wang, et al.
Cancer Chemotherapy and Pharmacology|April 23, 2003
Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly scheduleXiao-Du Guo, Nancy Harold, M Wasif Saif, et al.
Nucleic Acid Therapeutics|April 1, 2022
An Integrative Multi-Omics Analysis Reveals MicroRNA-143 as a Potential Therapeutic to Attenuate Retinal AngiogenesisJiang-Hui Wang, Yu-Fan Chuang, Jinying Chen, et al.
Journal of Virology|August 10, 2012
HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteinsYuxing Li, Sijy O'Dell, Richard Wilson, et al.
Frontiers in Immunology|August 9, 2024
mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodiesJavier Guenaga, Mehrdad Alirezaei, Yu Feng, et al.
JCO Clinical Cancer Informatics|April 18, 2019
A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the ClinicManuela Salvucci, Arman Rahman, Alexa J Resler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2011
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignanciesDavid Olmos, Douglas Barker, Rohini Sharma, et al.
Cellular and Molecular Life Sciences : CMLS|August 4, 2019
Two of a kind: transmissible Schwann cell cancers in the endangered Tasmanian devil (Sarcophilus harrisii)Amanda L Patchett, Tim H H Coorens, Jocelyn Darby, et al.
Pageof 27